MedPath

Clinical Trial to Evaluate the Efficacy and Safety of OC-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease

Phase 3
Completed
Conditions
Dry Eye Disease
Interventions
Registration Number
NCT05378945
Lead Sponsor
Ji Xing Pharmaceuticals (Shanghai) Co., Ltd.
Brief Summary

The objective of this study is to evaluate the safety and effectiveness of OC-01 (varenicline solution) Nasal Spray as compared to placebo (vehicle) on signs and symptoms of dry eye disease.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
340
Inclusion Criteria
  • Have used and/or desired to use an artificial tear substitute for dry eye symptoms within 6 months prior to the Screening Visit
Exclusion Criteria
  • Have had any intraocular surgery (such as cataract surgery) or extraocular surgery in either eye within three months or refractive surgery (e.g., laser-assisted in-situ keratomileusis, laser epithelial keratomileusis, photorefractive keratectomy or corneal implant) within 12 months of the Screening Visit
  • Have a history or presence of any ocular disorder or condition in either eye that would, in the opinion of the Investigator, likely interfere with the interpretation of the study results or participant safety such as significant corneal or conjunctival scarring; pterygium or nodular pinguecula; current ocular infection, acute conjunctivitis, or inflammation not associated with dry eye; anterior (epithelial) basement membrane corneal dystrophy or other clinically significant corneal dystrophy or degeneration; ocular herpetic infection; evidence of keratoconus; etc. Blepharitis not requiring treatment and mild meibomian gland disease that are typically associated with DED are allowed.
  • Have a systemic condition or disease not stabilized or judged by the Investigator to be incompatible with participation in the study (e.g., current systemic infection, uncontrolled autoimmune disease, uncontrolled immunodeficiency disease, history of myocardial infarction or heart disease, etc.)
  • Have a known hypersensitivity to any of the procedural agents or investigational product components
  • Have any condition or history that, in the opinion of the investigator, may interfere with study compliance, outcome measures, safety parameters, and/or the general medical condition of the subject.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
OC-01Varenicline Tartrate Nasal Spray-
PlaceboPlacebo (vehicle)-
Primary Outcome Measures
NameTimeMethod
Schirmer's Test Score28 days

Percentage of subjects who achieve ≥10 mm improvement in Schirmer's Test Score from baseline

Secondary Outcome Measures
NameTimeMethod
Mean change from Baseline in Schirmer's Test Score (STS)28 days

Schirmer's test scores are from 0-35 mm where a higher score is indicative of a better outcome.

Mean change from Baseline in Eye Dryness Score (EDS)28 days/ 14 days/ 7days

Eye dryness score is assessed on a visual analogue scale with scores ranging from 0 to 100 (0=no discomfort; 100=maximal discomfort) and lower scores indicate a better outcome

Trial Locations

Locations (20)

Henan Eye Hospital

🇨🇳

Zhengzhou, Henan, China

The Second Hospital of Anhui Medical University

🇨🇳

Hefei, Anhui, China

Peking University Third Hospital

🇨🇳

Beijing, Beijing, China

Beijing Tongren Hospital

🇨🇳

Beijing, Beijing, China

The Affiliated Hospital of Guizhou Medical University

🇨🇳

Guiyang, Guizhou, China

Beijing Hospital

🇨🇳

Beijing, Beijing, China

Zhujiang Hospital of Southern Medical University

🇨🇳

Guangzhou, Guangdong, China

Hebei Eye Hospital

🇨🇳

Xingtai, Hebei, China

Shijiazhuang People's Hospital

🇨🇳

Shijiazhuang, Hebei, China

The First Affiliated Hospital of Harbin Medical University

🇨🇳

Harbin, Heilongjiang, China

Union Hospital Tongji Medical College Huazhong University of Science and Technology

🇨🇳

Wuhan, Hubei, China

Wuhan Aier Eye Hospital Hankou Hospital

🇨🇳

Wuhan, Hubei, China

Nanjing First Hospital

🇨🇳

Nanjing, Jiangsu, China

The First Bethune Hospital of Jilin University

🇨🇳

Changchun, Jilin, China

Eye Hospital of Shandong First Medical University

🇨🇳

Jinan, Shandong, China

Weifang Eye Hospital

🇨🇳

Weifang, Shandong, China

Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine

🇨🇳

Shanghai, Shanghai, China

Tongji Hospital of Tongji University

🇨🇳

Shanghai, Shanghai, China

Tianjin Medical University Eye Hospital

🇨🇳

Tianjin, Tianjin, China

The Second Affiliated Hospital Zhejiang University School of Medicine

🇨🇳

Hangzhou, Zhejiang, China

© Copyright 2025. All Rights Reserved by MedPath